Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific share repurchase transaction executed on September 1, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Purchase Price Range: Highest price of 1,330 pence per share; lowest price of 1,295 pence per share.
- Treasury Holdings (Settled): 503,996,816 shares (9.03% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,396,816 shares (9.94% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,075,896,667 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 400,000 shares on September 1, 2011. Consequently, the percentage of shares held in Treasury increased to 9.94% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,075,896,667) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.94% including unsettled shares).
- Review the specific price range paid (1,295 to 1,330 pence) for the September 1 repurchase.